Literature DB >> 8370571

Pharmacokinetics of apomorphine in parkinsonian patients.

E Nicolle1, P Pollak, F Serre-Debeauvais, P Richard, C L Gervason, E Broussolle, M Gavend.   

Abstract

Apomorphine, a dopamine agonist, has been used efficiently in parkinsonian patients to treat severe levodopa-induced on-off phenomenon. Motor improvement has been obtained both with continuous subcutaneous (SC) infusions, and multiple SC injections. So as to assist in the understanding of the clinical results, we studied the peripheral pharmacokinetics of apomorphine in 20 patients after intravenous (IV) or SC injections in the anterior abdominal wall and in the thigh at various doses, or SC infusion. Plasma apomorphine levels were measured by high-performance liquid chromatography with electrochemical detection. After an SC injection in the abdominal wall, the Tmax was brief (16 +/- 11 min) the drug was rapidly cleared from the plasma and had a short plasma half-life (69.7 +/- 25.8 min). The AUC was similar following SC and IV injections, suggesting that apomorphine was completely absorbed from subcutaneous tissue. Inter-subject variability in drug absorption was large. We noticed a trend towards a more complete absorption following injection in the abdominal wall rather than in the thigh. In patients chronically treated by continuous SC infusion, the apparent plasma half-life was five times longer than that following SC or IV injections. These pharmacokinetic data may explain the rapid onset and brief duration of clinical effects, and the usefulness of individual titration for intermittent SC apomorphine injections, and the smoother motor response obtained with continuous SC infusions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370571     DOI: 10.1111/j.1472-8206.1993.tb00238.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  14 in total

Review 1.  Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.

Authors:  C Neef; T van Laar
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 2.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

3.  A study of tolerance to apomorphine.

Authors:  J L Montastruc; M E Llau; J M Senard; M A Tran; O Rascol; P Montastruc
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Naloxone does not prevent apomorphine-induced emesis or hypotension in dogs.

Authors:  J L Montastruc; M Lapeyre-Mestre; M E Llau; J M Senard; O Rascol; P Montastruc
Journal:  Clin Auton Res       Date:  1994-12       Impact factor: 4.435

Review 5.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

6.  Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.

Authors:  K Pietz; P Hagell; P Odin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154

Review 7.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

8.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

9.  S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis.

Authors:  Richard J Mead; Adrian Higginbottom; Scott P Allen; Janine Kirby; Ellen Bennett; Siân C Barber; Paul R Heath; Antonio Coluccia; Neelam Patel; Iain Gardner; Andrea Brancale; Andrew J Grierson; Pamela J Shaw
Journal:  Free Radic Biol Med       Date:  2013-04-19       Impact factor: 7.376

Review 10.  Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?

Authors:  K Ray Chaudhuri; Alexandra Rizos; Kapil D Sethi
Journal:  J Neural Transm (Vienna)       Date:  2013-03-02       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.